Saturday, July 28, 2018

Hyatt Regency Tamaya Resort and Spa
Tamaya Ballroom FGH
Santa Ana Pueblo, NM

7:00 pm - 7:30 pm Registration and Dinner
7:30 pm - 9:00 pm CME-certified Symposium

Slide to view more

Program Overview

As clinical data emerge regarding the benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, obtaining access to these agents remains a barrier to their use. Given the high prevalence of patients on statin therapy who fail to meet low-density lipoprotein cholesterol (LDL-C) target goals, continuing education is crucial regarding the latest clinical advances and recommendations for the use of PCSK9 inhibitors, as well as practical strategies to gain access to these agents to improve patient outcomes. This educational activity will feature a panel of experts who will review the latest recommendations for the use of PCSK9 inhibitors in prevention and the impact of their use on cardiovascular outcomes. They will also assess the latest data on the benefits and safety of achieving low LDL-C goals, as well as detail practical strategies to improve access to treatment. Clinical cases will be presented to highlight the key educational objectives.


7:30 pm – 7:40 pm Introduction and Pretest
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
7:40 pm – 8:00 pm An Update on PCSK9 Inhibitors: Identifying Patients Who May Benefit and Gaining Access
Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
8:00 pm – 8:45 pm Clinical Cases
Moderated by Michael H. Davidson, MD, FACC, FACP, FNLA
8:45 pm – 8:50 pm Posttest
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
8:50 pm – 9:00 pm Question and Answer

Slide to view agenda

CME Information

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the treatment of patients with dyslipidemia.

Learning Objectives

Upon successful completion of this activity, participants will be able to:

  • Identify patients with hypercholesterolemia who may benefit from LDL-C reduction with a PCSK9 inhibitor.
  • Utilize PCSK9 inhibitors in accordance with the latest clinical evidence.
  • Implement appropriate strategies to improve access to PCSK9 inhibitors.